{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"data_sharing_plan":["IPD Sharing (as of January 2022): No"],"condition":["Colorectal Neoplasms"],"disease":["Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2198817"],"location":["United States"],"study_start_month":["3"],"keyword":["Immunotherapy","Liver lesion","MEDI6469","Anti-OX40 antibody","Metastatic colorectal cancer"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer","description":"This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.","dates":{"creation":"2016-03-15"},"accession":"2198817","cross_references":{"ClinicalTrials___gov":["NCT02559024"]}}